Tuberous Sclerosis Clinical Trial
— TESSTALOfficial title:
A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Verified date | April 2008 |
Source | Cardiff University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Status | Unknown status |
Enrollment | 14 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - If female, documentation of negative pregnancy test prior to enrolment. - Participants, including males, must use an effective form of contraception, whilst taking sirolimus and for twelve weeks after stopping the drug - One or more renal angiomyolipomata of at least two centimetres or greater in largest diameter - Adequate renal function :glomerular filtration rate > 40 ml/min - Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria) or sporadic LAM (biopsy-proven or compatible high resolution chest CT scan and respiratory function tests.) - Signed and dated informed consent Exclusion Criteria: - History of non-compliance or inability to give informed consent - Significant haematological or hepatic abnormality (i.e. transaminase levels > 150 i.u./L serum albumin < 30 g/L, haematocrit< 30%, platelets < 100,000/ mm3, adjusted absolute neutrophil count < 1,500/mm3, total WBC < 3,000/ mm3) - Greater than 1 g proteinuria daily - Multiple bilateral AMLs, where individual lesions cannot be distinguished - Renal haemorrhage within preceding year - In those who have had a renal haemorrhage, known conservatively managed renal aneurysm(s) greater than 10mm - Patients who have had embolisation for AML(s) within the preceding 6 months - Patients who are unable to walk 100 metres on the flat - Continuous requirement for supplemental oxygen - Patients who have had or are being considered for organ transplant - Uncontrolled hyperlipidaemia - Intercurrent infection at initiation of Sirolimus - Surgery within last 2 months - Pregnant or lactating women - Use of an investigational drug within the last 30 days - Change in anti epileptic drug medication within the last 3 months - Likely to need vaccination e.g. for travel during the course of the trial (except for influenza vaccine in patients with LAM) - Current usage of strong inhibitors of CYP3AE ( such as ketoconazole, voriconazole, itraconazole, tilithromycin or clarithromycin) or strong inducers (such as rifampicin or rifabutin) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Sussex County Hospital | Brighton | |
United Kingdom | University Hospital of Wales | Cardiff | Wales |
United Kingdom | City Hospital | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Cardiff University | Royal Sussex County Hospital, St Georges Hospital Medical School, The Tuberous Sclerosis Association, University of Nottingham, Wyeth is now a wholly owned subsidiary of Pfizer |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 | assessments at baseline and 2,6,12 and 24 months | ||
Primary | toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events | throughout study | ||
Secondary | respiratory function tests (FEV1, FVC, DLCO), cognitive function (memory, executive skills) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
Recruiting |
NCT03422367 -
JASPER Early Intervention for Tuberous Sclerosis
|
N/A | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT02104011 -
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
|
Phase 2 | |
Recruiting |
NCT02461459 -
Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
|
||
Completed |
NCT01526356 -
Topical Rapamycin to Erase Angiofibromas in TSC
|
Phase 2 | |
Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
Terminated |
NCT01092208 -
Studies of Autistic Patients: Gene Networks and Clinical Subtypes
|
||
Active, not recruiting |
NCT01954693 -
A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
|
Phase 2 | |
Completed |
NCT03826628 -
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
Recruiting |
NCT05286632 -
KidneYou - Innovative Digital Therapy
|
N/A | |
Withdrawn |
NCT04344626 -
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
|
N/A | |
Recruiting |
NCT05199402 -
Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
|
||
Recruiting |
NCT00001975 -
Study of Skin Tumors in Tuberous Sclerosis
|